Ongoing work includes preparation for an investigational new drug application to initiate human trials to address the unmet medical needs of patients with ATM and ultimately extend therapeutic benefit to non-ATM α-thalassemia patients who are transfusion dependent, as seen in alpha thalassemia intermedia (hemoglobin H disease). Here, ATM is linked to hemoglobin H disease.